Sarah B Goldberg MD, MPH

Assistant Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Thoracic Oncology Program

Medical Oncology

Education & Training

  • M.P.H., Harvard School of Public Health
  • M.D., Mount Sinai School of Medicine (2006)
  • Resident, Massachusetts General Hospital , Internal Medicine  (2006 - 2009)
  • Fellow, Dana-Farber Cancer Institute, Massachusetts General Hospital , Medical Oncology  (2009 - 2012)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Lung Cancer; Thoracic Oncology; Personalized Medicine


Cancers Treated

Lung, Mesothelioma, Thymomas


Board Certifications

  • Hematology, Internal Medicine, Board Eligible
  • Internal Medicine, Board Certified (2009)
  • Medical Oncology, Board Certified (2012)

Clinical Trials

Conditions Study Title
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lung and Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Lung A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Lung A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

More Clinical Trials...

Edit Profile